![](https://emeatribune.com/wp-content/uploads/2024/05/johnson-johnson-will-pay-6-5-billion-to-resolve-nearly-all-talc-ovarian-cancer-lawsuits-in-u-s-980x644.jpg)
![](https://emeatribune.com/wp-content/uploads/2024/05/johnson-johnson-will-pay-6-5-billion-to-resolve-nearly-all-talc-ovarian-cancer-lawsuits-in-u-s-980x644.jpg)
![](https://image.cnbcfm.com/api/v1/image/107363243-1706035367989-gettyimages-1480096596-0j5a5875_rjbkkqvw.jpeg?v=1714559291&w=1920&h=1080)
Johnson & Johnson baby powder is displayed in San Anselmo, California, on April 5, 2023.
Justin Sullivan | Getty Images
Johnson & Johnson on Wednesday said it will pay $6.5 billion to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer.
The deal would allow J&J to resolve the lawsuits through a third bankruptcy filing of a subsidiary company, LTL Management.
It will begin a three-month voting period for claimants, in hopes of reaching a consensus on a settlement of all current and future ovarian cancer claims. About 99% of the talc-related lawsuits filed against J&J and its subsidiaries stem from ovarian cancer.
J&J said the remaining pending lawsuits relate to a rare cancer called mesothelioma and will be addressed outside of the new settlement plan.
The pharmaceutical giant said it has already resolved 95% of mesothelioma lawsuits filed to date.
This story is developing. Please check back for updates.
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel